ESC 365 - Antithrombotic therapy in stable cardiovascular disease - Represented in NEJM by the COMPASS trial and the PEGASUS-TIMI 54 trial

ESC Premium Access

Antithrombotic therapy in stable cardiovascular disease - Represented in NEJM by the COMPASS trial and the PEGASUS-TIMI 54 trial

Session: Highlights from the New England Journal of Medicine: Editors’ Choice

Topic: Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)

Speaker: Doctor J. Eikelboom (Hamilton, CA)

Event: ESC Congress 2018

Congress Presentation

Add to my library

About the speaker

Doctor John William Eikelboom

McMaster University, Hamilton (Canada)

37 presentations

0 follower

3 more presentations in this session

Antithrombotic therapy in patients with atrial fibrillation undergoing PCI – Represented in NEJM by the PIONEER-AF PCI trial and the RE-DUAL PCI trial

Speaker: Professor C. Cannon (Boston, US)

Fractional Flow Reserve-Guided PCI – represented in NEJM by the FAME, FAME-2, Compare-Acute, IFR-SWEDEHEART, and DEFINE-FLAIR trials

Speaker: Professor E. Barbato (Rome, IT)

PFO closure for cryptogenic stroke – Represented in NEJM by the CLOSURE I, PC, REDUCE, CLOSE, and RESPECT trials

Speaker: Professor L. Sondergaard (Copenhagen, DK)

Access the full session

Highlights from the New England Journal of Medicine: Editors’ Choice

Speakers: Doctor J. Eikelboom, Professor C. Cannon, Professor E. Barbato, Professor L. Sondergaard

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources